(XBI) SPDR S&P Biotech - Ratings and Ratios

The SPDR® S&P Biotech ETF (XBI) is designed to replicate the performance of the S&P Biotechnology Select Industry Index, which is a subset of the S&P Total Market Index (S&P TMI). The fund utilizes a sampling strategy to achieve its investment objective, typically allocating 80% to 100% of its assets to securities included in the index. This index focuses on companies in the biotechnology sector, offering exposure to a broad range of firms involved in biotech research, development, and production. The ETF provides investors with a cost-effective way to gain diversified exposure to the biotechnology industry, which is known for its high growth potential but also its volatility.

As of the latest data, XBI has an average trading volume of 14,066,400 shares over the past 20 days, with a last price of $80.25. Its short-term moving average (SMA 20) stands at $76.86, while the medium-term SMA 50 is at $83.58. The long-term SMA 200 is at $93.33, indicating a recent downtrend. The Average True Range (ATR) of $3.14 reflects moderate volatility. The fund manages assets under management (AUM) of $4,751.05 million, making it a significant player in the biotech ETF space.